Napabucasin,
panobinostat, and
quisinostat were purchased from Selleckchem and
A1331852 and
Navitoclax from Chemietek, diluted in DMSO to make stock solutions, aliquoted and stored at −80C.
Napabucasin was formulated by heating to 50C for 10 minutes and then sequentially adding 45%
PEG300 (Sigma), 5%
Tween80 (Sigma) and 45% sterile water, with vortexing after adding each component (Selleckchem).
panobinostat was formulated by sequentially adding 48%
PEG300 (Sigma), 2%
Tween80 (Sigma) and 48% sterile water, with vortexing after adding each component (Selleckchem).
quisinostat was formulated in 10%
hydroxypropyl-b-cyclodextrin (Sigma), 25 mg/ml
mannitol (Sigma), in sterile water(45 (
link)).
A1331852 was formulated by sequentially adding 10% Ethanol (Fisher), 60%
Phosal 50 PG (Lipoid), and 30%
PEG400 (Sigma), and vortexing (MedChemExpress).
Navitoclax was formulated in 10% ethanol (Fisher), 30%
PEG400 (Sigma), and 60%
Phosal 50 PG (Lipoid), with vortexing after adding each component (MedChemExpress). Sorafenib was formulated in 90% corn oil (Selleckchem) with vortexing (MedChemExpress). Working solutions were made fresh prior to administration.
Lalazar G., Requena D., Ramos-Espiritu L., Ng D., Bhola P.D., de Jong Y.P., Wang R., Narayan N.J., Shebl B., Levin S., Michalidis E., Kabbani M., Vercauteren K.O., Hurley A.M., Farber B.A., Hammond W.J., Saltsman JA I.I.I., Weinberg E.M., Glickman J.F., Lyons B.A., Ellison J., Schadde E., Hertl M., Leiting J.L., Truty M.J., Smoot R.L., Tierney F., Kato T., Wendel H.G., LaQuaglia M.P., Rice C.M., Letai A., Coffino P., Torbenson M.S., Ortiz M.V, & Simon S.M. (2021). Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening. Cancer discovery, 11(10), 2544-2563.